欧洲共识:四因子凝血酶原复合物在心脏与非心脏手术中的应用
欧洲心胸麻醉学会输血与止血小组系统综述四因子凝血酶原复合物(4F-PCC)的剂量、疗效、安全性与监测证据,推荐大出血凝血病患者初始负荷25 IU.kg-1,血栓高风险心脏手术患者考虑半剂量12.5 IU.kg-1,第二次负荷视情况给予,围术期可用特定床旁检测指导治疗。
要点
- 大出血凝血病患者初始负荷推荐25 IU.kg-1。
- 血栓高风险如心脏手术考虑半剂量12.5 IU.kg-1。
- 凝血病与微血管出血持续且排除其他原因可给第二次负荷。
核心结论
- 4F-PCC对多种出血场景有疗效证据,但缺乏令人信服的安全性数据。
研究设计与样本
- 欧洲心胸麻醉学会输血与止血小组对4F-PCC进行系统文献综述。
主要发现
- 已汇总4F-PCC在不同场景下的剂量、疗效、药物安全与监测策略证据。
关键数值与推荐
- 大出血凝血病患者初始负荷推荐25 IU.kg-1,适用于维生素K拮抗剂急性逆转、止血复苏尤其创伤、无特异性拮抗剂时直接口服抗凝药逆转。
- 血栓并发症高风险患者如心脏手术应考虑初始半剂量负荷12.5 IU.kg-1。
- 凝血病与微血管出血持续且其他出血原因基本排除时可能需第二次负荷。
- 围术期监测与指导4F-PCC治疗可使用组织因子激活、因子VII依赖且肝素不敏感的床旁检测。
临床怎么用
- 依据出血场景与血栓风险选择4F-PCC初始负荷剂量,并用特定床旁检测指导围术期治疗。
局限性
- 缺乏令人信服的安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Modern four-factor prothrombin complex concentrate was designed originally for rapid targeted replacement of the coagulation factors II, VII, IX and X. Dosing strategies for the approved indication of vitamin K antagonist-related bleeding vary greatly. They include INR and bodyweight-related protocols as well as fixed dose regimens. Particularly in the massively bleeding trauma and cardiac surgery patient, four-factor prothrombin complex concentrate is used increasingly for haemostatic resuscitation. Members of the Transfusion and Haemostasis Subcommittee of the European Association of Cardiothoracic Anaesthesiology performed a systematic literature review on four-factor prothrombin complex concentrate. The available evidence has been summarised for dosing, efficacy, drug safety and monitoring strategies in different scenarios. Whereas there is evidence for the efficacy of four-factor prothrombin concentrate for a variety of bleeding scenarios, convincing safety data are clearly missing. In the massively bleeding patient with coagulopathy, our group recommends the administration of an initial bolus of 25 IU.kg-1 . This applies for: the acute reversal of vitamin K antagonist therapy; haemostatic resuscitation, particularly in trauma; and the reversal of direct oral anticoagulants when no specific antidote is available. In patients with a high risk for thromboembolic complications, e.g. cardiac surgery, the administration of an initial half-dose bolus (12.5 IU.kg-1 ) should be considered. A second bolus may be indicated if coagulopathy and microvascular bleeding persists and other reasons for bleeding are largely ruled out. Tissue-factor-activated, factor VII-dependent and heparin insensitive point-of-care tests may be used for peri-operative monitoring and guiding of prothrombin complex concentrate therapy.
引用
- Erdoes G, Koster A, Ortmann E, et al. A European consensus statement on the use of four-factor prothrombin complex concentrate for cardiac and non-cardiac surgical patients. Anaesthesia. 2020. PMID: 32681570. doi:10.1111/anae.15181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。